Please try another search
Investing.com - RBC Capital raised its price target on Biogen Inc. (NASDAQ:BIIB) to $260 from $240 while maintaining an Outperform rating on the shares. The stock currently trades at $218.12, near its...
Investing.com - Veeva Systems announced that Biogen has committed to Vault CRM globally, according to a press release issued today. Biogen sits just outside the top 20 pharmaceutical companies on some...
Apellis Pharmaceuticals Inc. (APLS) announced results from a five-year analysis of its GALE extension study showing that SYFOVRE delayed geographic atrophy lesion growth by approximately 1.5 years...
Instrument Type
Region
Sector
Industry
Date
Category
Provider